Humacyte, Inc.
For the period ended Jun 30, 2026. Filed Aug 12, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2026 · Filed Aug 12, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 5. Other Information
Director and Officer Trading Arrangements
On June 3, 2026, Laura E. Niklason, the Company’s President and Chief Executive Officer, adopted a trading arrangement for the sale of Common Stock that is intended to satisfy the affirmative defense conditions provided by Rule 10b5-1(c) under the Exchange Act (the “Niklason 10b5-1 Plan”). The Niklason 10b5-1 Plan provides for the first possible trade date of September 1, 2026 and terminates automatically on the earlier of the execution of all trades contemplated by the Niklason 10b5-1 Plan (or the expiration of all orders relating to such trades), or June 3, 2027. The Niklason 10b5-1 Plan provides for the potential sale of up to an aggregate of 214,420 shares of Common Stock pursuant to its terms.
Other than as disclosed above, during the three months ended June 30, 2026, no director or officer (as defined in Rule 16a-1(f) under the Exchange Act) of the Company adoptedor terminated any “Rule 10b5-1 trading arrangement” or any “non-Rule 10b5-1 trading arrangement,” as each term is defined in Item 408(a) of Regulation S-K.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.